This content is machine translated Diabetic nephropathy Dapagliflozin and pioglitazone are not inferior as lone fighters The treatment of diabetic nephropathy (DN) has made significant progress in the past. Nevertheless, the number of diabetic patients who ultimately develop end-stage renal disease remains high. A combination of…
View Post 5 min This content is machine translated Chronic renal failure in type 2 diabetes Using nephroprotective therapy options and slowing progression In type 2 diabetics, renal function should be checked at regular intervals. Nowadays, modern treatment approaches are available that can slow down the progression of diabetic nephropathy. If early use…
View Post 5 min This content is machine translated Diabetic nephropathy Gliflozines may slow progression of renal failure Nephropathy as a late complication of diabetes is a common cause of renal failure requiring dialysis. In the CREDENCE trial, SGLT-2 inhibitors slowed the progression of renal dysfunction in diabetic…
View Post 3 min This content is machine translated Diabetic kidney disease Canagliflozin approved in fast track for diabetic nephropathy Kidney protection is extremely important for diabetes sufferers. Recently, canagliflozin became the first SGLT-2 inhibitor in Switzerland to receive a marketing authorization extension to reduce the risk of progression to…
View Post 3 min This content is machine translated Diabetic nephropathy Inhibition of sodium-glucose transporter type 2 has a renoprotective effect Diabetic nephropathy is the most common cause of chronic kidney failure – and one of the most common consequences of diabetes mellitus. The introduction of sodium-glucose transporter type 2 (SGLT2)…
View Post 9 min This content is machine translated Chronic renal failure How can progression be prevented? To slow the progression of chronic kidney disease, there are disease-specific and nonspecific measures. Basic diagnostics for chronic renal failure include urine status and sonography of the kidneys. If the…
